whi p154 and tofacitinib

whi p154 has been researched along with tofacitinib in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baker, DL; Ball, DJ; Beals, CR; Beckius, GE; Blumenkopf, TA; Borie, DC; Brissette, WH; Brown, MF; Casavant, JM; Changelian, PS; Conklyn, MJ; Des Etages, SG; Doty, JL; Elliott, EA; Finco-Kent, D; Fisher, DA; Fisher, MB; Flanagan, ME; Gaweco, AS; Hayes, LS; Higgins, J; Hines, M; Holm, B; Johnson, KS; Kawabata, TT; Kent, CR; Koslov, ER; Kudlacz, EM; Larson, M; Lillie, BM; Littman, BH; Magna, HA; Magnuson, KS; Martin, WH; McCurdy, SP; Milici, AJ; Morris, RE; Moyer, JD; Munchhof, MJ; Nelms, LF; O'Shea, JJ; Paniagua, R; Perry, BD; Reitz, B; Rizzuti, BJ; Saltarelli, MJ; Sawyer, PS; Shang-Poa, C; Si, MS; Smith, JF; Strelevitz, TJ; Su, C; Subramanyam, C; Sun, J; Whipple, DA; Woodworth, TG; Yoon, K; Zagouras, P; Zhou, YJ	1
Aubert, JD; Golshayan, D; Juillerat-Jeanneret, L; Mikulic, J	1

Studies

Baker, DL; Ball, DJ; Beals, CR; Beckius, GE; Blumenkopf, TA; Borie, DC; Brissette, WH; Brown, MF; Casavant, JM; Changelian, PS; Conklyn, MJ; Des Etages, SG; Doty, JL; Elliott, EA; Finco-Kent, D; Fisher, DA; Fisher, MB; Flanagan, ME; Gaweco, AS; Hayes, LS; Higgins, J; Hines, M; Holm, B; Johnson, KS; Kawabata, TT; Kent, CR; Koslov, ER; Kudlacz, EM; Larson, M; Lillie, BM; Littman, BH; Magna, HA; Magnuson, KS; Martin, WH; McCurdy, SP; Milici, AJ; Morris, RE; Moyer, JD; Munchhof, MJ; Nelms, LF; O'Shea, JJ; Paniagua, R; Perry, BD; Reitz, B; Rizzuti, BJ; Saltarelli, MJ; Sawyer, PS; Shang-Poa, C; Si, MS; Smith, JF; Strelevitz, TJ; Su, C; Subramanyam, C; Sun, J; Whipple, DA; Woodworth, TG; Yoon, K; Zagouras, P; Zhou, YJ

Aubert, JD; Golshayan, D; Juillerat-Jeanneret, L; Mikulic, J

Reviews

1 review(s) available for whi p154 and tofacitinib

Article	Year
Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction. Journal of medicinal chemistry, 2018, 11-21, Volume: 61, Issue:22 Topics: Animals; Drug Discovery; Fibrosis; Humans; Molecular Targeted Therapy; Organ Specificity	2018

Other Studies

1 other study(ies) available for whi p154 and tofacitinib

Article	Year
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science (New York, N.Y.), 2003, Oct-31, Volume: 302, Issue:5646 Topics: Animals; Enzyme Inhibitors; Gene Expression Regulation; Graft Rejection; Graft Survival; Heart Transplantation; Humans; Immunosuppressive Agents; Interleukin-2; Janus Kinase 3; Kidney Transplantation; Lymphocyte Activation; Lymphocyte Count; Lymphocyte Culture Test, Mixed; Lymphocyte Subsets; Macaca fascicularis; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Myocardium; Piperidines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Transplantation, Heterotopic; Transplantation, Homologous; Tumor Cells, Cultured	2003

Article

Year

Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.

Science (New York, N.Y.), 2003, Oct-31, Volume: 302, Issue:5646

Topics: Animals; Enzyme Inhibitors; Gene Expression Regulation; Graft Rejection; Graft Survival; Heart Transplantation; Humans; Immunosuppressive Agents; Interleukin-2; Janus Kinase 3; Kidney Transplantation; Lymphocyte Activation; Lymphocyte Count; Lymphocyte Culture Test, Mixed; Lymphocyte Subsets; Macaca fascicularis; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Myocardium; Piperidines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Transplantation, Heterotopic; Transplantation, Homologous; Tumor Cells, Cultured

2003